WO 2004/016633 PCT/GB2003/003562

## Claims

1. A hydrobromide salt of morphine-6- $\beta$ -D-glucuronide (M6G.HBr).

5

- 2. A pharmaceutical composition comprising an analysesically effective amount of M6G.HBr together with a pharmaceutically acceptable carrier, excipient, or diluent.
- 3. A pharmaceutical composition comprising an amount of M6G.HBr effective for the treatment of breathlessness in a subject with advanced cancer, together with a pharmaceutically acceptable carrier, excipient, or diluent.
- 15 4. M6G.HBr for use as a medicament.
  - 5. Use of M6G.HBr in the manufacture of a medicament for the treatment of pain.
- 20 6. Use according to claim 5 for the treatment of moderate to severe pain in acute or chronic conditions.
  - 7. Use of M6G.HBr in the manufacture of a medicament for the treatment of breathlessness in a subject with advanced cancer.

25

- 8. A method of treating pain which comprises administering a subject with an analgesically effective amount of M6G.HBr.
- 9. A method of treating breathlessness in a subject with advanced cancer which comprises administering the subject with an amount of M6G.HBr which is effective for reducing breathlessness.
  - 10. A method of making M6G.HBr which comprises:
- 35 (i) contacting a hydrogen bromide solution with a solution of M6G in methanol;

WO 2004/016633 PCT/GB2003/003562

(ii) contacting the solution resulting from step (i) with an organic solvent to precipitate M6G.HBr; and (iii) isolating M6G.HBr precipitated in step (ii).

- 5 11. A method according to claim 10, in which the solutions and solvent are at -15°C, or below.
  - 12. A method according to claim 10 or 11, which further comprises washing the precipitated M6G.HBr to minimise the amount of organic solvent present.

10

- 13. A method according to claim 12, in which the precipitated M6G.HBr is washed with diethyl ether.
- 15 14. A method according to any of claims 10 to 13, in which the organic solvent of step (ii) is 2-propanol.